Long COVIDNCT05848401
Biosound Therapy as a Treatment for Long COVID Patients
A study testing Biosound Therapy System in people with Long COVID, run by Anxiety Relief Center at 1 site in United States.
Trial summary
This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID. Read more about this study
- Who is it for?
- Ages 20 to 65 years
- Conditions the study is for
- Long COVID
- What is being tested?
- Biosound Therapy System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 13 participants
- Where
- 1 siteUnited States
- Study dates
- 29 Apr 2021to 19 Jan 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- experiencing at least three symptoms that began or were intensified due to COVID
- able to provide documentation of a COVID-19 test older than 30 days.
- 20-65 years old.
Who cannot join
- abusing alcohol or drugs
- having a pacemaker or any other implanted devices
- pregnancy
- history of the following conditions: blood clots, schizophrenia, seizures, recent head injury, and any acute physical injury
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Biosound Therapy as a Treatment for Long COVID Patients: A Randomized Pilot Trial
This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID.
The goal of this clinical trial is to learn about Biosound Therapy System's impact on long COVID symptoms. The main questions it aims to answer are:
Read more
- How does Biosound Therapy impact long COVID symptoms?
- Is the protocol for this trial feasible for a future full-scale Randomized Controlled Trial?
Participants with long COVID symptoms will be assigned to a control group and treatment group. The control group will receive no treatment. The treatment group will have 8 sessions of Biosound Therapy. Researchers will compare the treatment and control group to see if there's a difference in long COVID symptoms.
Read the detailed description
Investigators will recruit participants through social media and word of mouth. They will also share the study information with practitioners, businesses, organizations, research departments, universities, and the community. Participants will email or call The Anxiety Relief Center to inquire about participating in the study.
Initial screening procedures will take place using the receptionist script to determine eligibility of participants. Eligible participants who agree to participate in the study will then be asked to come into the office for an intake at a time convenient for them. This appointment will include signing the consent form and the completion of initial assessments: Cambridge Brain Sciences tasks, PHQ9, GAD7, and the COVID-19 Persistent Symptom Questionnaire.
After a participant has completed the initial intake appointment, the participant will be randomly assigned to the treatment or control group using Randomizer.org, a computer-generated randomizer. Each participant will be informed if they were assigned to the treatment or control group. An investigator will schedule two Biosound Therapy sessions per week for four weeks with every participant in the treatment group.
The Biosound Therapy System (BTS) is a system that utilizes biofeedback, vibroacoustic technology, and binaural beats. Vibroacoustic Technology uses sinusoidal, low-frequency, rhythmical pulsing sound waves in conjunction with music. The BTS device does not send electricity through the body; rather, the device uses amplifiers embedded into an adjustable bed to send frequencies between 40 and 70 Hz into the body.
At the beginning of the BTS session, the participant will complete the "Biosound Technologies Pretest" questionnaire and then will be instructed to sit on the BTS platform to begin utilizing HeartMath technology that will collect data on heart rate variability (HRV). An investigator will assist the client in attaching a finger sensor around their index finger as they recline onto the platform so that they are facing a monitor positioned in front of the platform. The monitor digitally portrays the participant's HRV and allows the participant to visually see how the rate of their breath is connected to their HRV. The participant spends a few minutes trying to match their breath rate with a moving icon called a breath pacer that is shown on the monitor. The icon moves up and down at the rate of the client's target heart rate. The monitor also displays corresponding coherence levels, which refer to the stability and balance between the brain and nervous system (HeartMath Institute, 2016). The coherence levels are color coordinated with the levels of low, medium, and high. A high coherence level signifies high stability, balance, and regulation, whereas a low coherence level signifies instability, imbalance, and dysregulation. A person with a high coherence level can operate with high efficiency. Once the participant improves their coherence level and HRV (about 5-10 minutes), an investigator will remove the finger sensor and instruct the participant to put on headphones.
Then, an investigator will begin a playlist that includes music with binaural beats that is synchronized with sound massage. Once the playlist has begun, an investigator will turn off the lights and exit the room until the playlist is finished. The session ends with video content. Each participant will be given an identical playlist for each session. At the end of the session, the participant will complete the "Biosound Technologies Posttest" questionnaire to assess the perceived effects of the session.
All collected data will be deidentified and stored in a HIPAA compliant electronic medical record system called Therapy Appointment. After a participant in the treatment group has completed their treatment sessions, they will complete the same assessments given at intake. After the assessments are completed, an investigator will ask 2 open-ended questions and then will record a summary of their answers.
While Biosound Therapy rarely causes side effects, some people may experience dizziness or discomfort. While adverse reactions are rarely reported, a decreased sense of anxiety can feel unfamiliar to people who are used to a state of physiological increased awareness. As stated above, the BTS is a wellness device that was designed to provide relief and side effects are rarely reported. All participants will be told that they can stop treatment at any time during the session by leaving the treatment room. An investigator will be in close proximity to the treatment room at all times to provide any needed assistance during participants' sessions. Snacks, water, guidance and emotional support will be available to participants should they experience any side effects. Additionally, HRV allows subjects an opportunity to see a balanced and healthy state and can help center a client who may be feeling dizzy after sound massage. The investigators will record any adverse side effects reported by the participants.
The process measures of recruitment and retention rates, open-ended interview responses, and participant characteristics will be summarized using descriptive statistics. Due to the small sample size, the Wilcoxon signed-rank test will be used to determine changes in the variables for the intervention and control group.
- Conditions
- Long COVID
- Being tested
- Biosound Therapy System
- Keywords
- long COVID, long haulers, post COVID syndrome, vibroacoustic therapy, biofeedback
- Medical subject headings
- Post-Acute COVID-19 Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Biosound Therapy SystemDevice
Also called vibroacoustic therapy, biofeedback, binaural beats
Biosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content.
| Study group | Role | What they receive |
|---|---|---|
| Treatment Group | Experimental | The treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content. Receives: Device: Biosound Therapy System |
| Control Group | No intervention | The control group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. Control group participants were given a complimentary Biosound Therapy session and a ten dollar gift card upon completion of their final assessments. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The Patient Health Questionnaire (PHQ-9)
9-item questionnaire assessing for Major Depressive Disorder
Measured: 4 weeks
Generalized Anxiety Disorder 7-item scale (GAD-7)
7-item questionnaire assessing for generalized anxiety disorder
Measured: 4 weeks
Cambridge Brain Sciences (CBS) tasks
The CBS tasks measure reasoning, short-term memory, and verbal ability through 12 online tasks simulating puzzles or video games.
Measured: 4 weeks
COVID-19 Persistent Symptom Questionnaire.
The authors developed The COVID-19 Persistent Symptom Questionnaire to measure common persistent COVID-19 symptoms at their worst over the last week on a scale of 0-3.
Measured: 4 weeks
Secondary outcomes (3)
Recruitment Rate
Recruiting individuals with long COVID symptoms into a trial of the Biosound Therapy System
Measured: Through study completion, an average of 1 year
Retention Rate
Retaining participants for a 4 week trial for the proposed battery of assessments. Retention rate (%) of participants enrolled into the trial who completed the 4 week protocol.
Measured: 4 weeks
Open-ended questions to participants about their experience
Participants will be asked, "1. Can you describe your experience receiving BTS in this study? 2. How did you perceive this treatment helping or not helping your symptoms?"
Measured: 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 May 2023
- Study start29 Apr 2021
- Primary completion5 Jan 2022
- Study completion19 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Long COVIDStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 13 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anxiety Relief Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Colleenia R Korapatti, MA, Principal investigator
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05848401
- Sponsor's protocol ID
- 21-ANXI-101
- Status last verified
- May 2023
- First submitted
- 5 May 2023
- Last updated
- 8 May 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Any researchers who are interested in replicating the study or using the de-identified IPD can contact the principal investigator for a copy of the data set.
Study at a glance
From the registry record, last updated by the sponsor on 8 May 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Biosound Therapy as a Treatment for Long COVID Patients: A Randomized Pilot Trial
- ClinicalTrials.gov ID
- NCT05848401
- Acronym / sponsor ID
- 21-ANXI-101
- Conditions
- Long COVID
- Keywords
- long COVID, long haulers, post COVID syndrome, vibroacoustic therapy, biofeedback
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 13 participants (actual)
- Lead sponsor
- Anxiety Relief CenterUniversity, hospital or other
- Study start
- 29 Apr 2021 (actual)
- Primary completion
- 5 Jan 2022 (actual)
- Study completion
- 19 Jan 2022 (actual)
- First posted
- 8 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to explore the impact of the Biosound Therapy Systerm on long COVID symptoms while determining feasibility of a future full-scale Randomized Controlled Trial. It was hypothesized that Biosound treatment would significantly improve long COVID.
The goal of this clinical trial is to learn about Biosound Therapy System's impact on long COVID symptoms. The main questions it aims to answer are:
- How does Biosound Therapy impact long COVID symptoms?
- Is the protocol for this trial feasible for a future full-scale Randomized Controlled Trial?
Participants with long COVID symptoms will be assigned to a control group and treatment group. The control group will receive no treatment. The treatment group will have 8 sessions of Biosound Therapy. Researchers will compare the treatment and control group to see if there's a difference in long COVID symptoms.
Detailed description
Investigators will recruit participants through social media and word of mouth. They will also share the study information with practitioners, businesses, organizations, research departments, universities, and the community. Participants will email or call The Anxiety Relief Center to inquire about participating in the study.
Initial screening procedures will take place using the receptionist script to determine eligibility of participants. Eligible participants who agree to participate in the study will then be asked to come into the office for an intake at a time convenient for them. This appointment will include signing the consent form and the completion of initial assessments: Cambridge Brain Sciences tasks, PHQ9, GAD7, and the COVID-19 Persistent Symptom Questionnaire.
After a participant has completed the initial intake appointment, the participant will be randomly assigned to the treatment or control group using Randomizer.org, a computer-generated randomizer. Each participant will be informed if they were assigned to the treatment or control group. An investigator will schedule two Biosound Therapy sessions per week for four weeks with every participant in the treatment group.
The Biosound Therapy System (BTS) is a system that utilizes biofeedback, vibroacoustic technology, and binaural beats. Vibroacoustic Technology uses sinusoidal, low-frequency, rhythmical pulsing sound waves in conjunction with music. The BTS device does not send electricity through the body; rather, the device uses amplifiers embedded into an adjustable bed to send frequencies between 40 and 70 Hz into the body.
At the beginning of the BTS session, the participant will complete the "Biosound Technologies Pretest" questionnaire and then will be instructed to sit on the BTS platform to begin utilizing HeartMath technology that will collect data on heart rate variability (HRV). An investigator will assist the client in attaching a finger sensor around their index finger as they recline onto the platform so that they are facing a monitor positioned in front of the platform. The monitor digitally portrays the participant's HRV and allows the participant to visually see how the rate of their breath is connected to their HRV. The participant spends a few minutes trying to match their breath rate with a moving icon called a breath pacer that is shown on the monitor. The icon moves up and down at the rate of the client's target heart rate. The monitor also displays corresponding coherence levels, which refer to the stability and balance between the brain and nervous system (HeartMath Institute, 2016). The coherence levels are color coordinated with the levels of low, medium, and high. A high coherence level signifies high stability, balance, and regulation, whereas a low coherence level signifies instability, imbalance, and dysregulation. A person with a high coherence level can operate with high efficiency. Once the participant improves their coherence level and HRV (about 5-10 minutes), an investigator will remove the finger sensor and instruct the participant to put on headphones.
Then, an investigator will begin a playlist that includes music with binaural beats that is synchronized with sound massage. Once the playlist has begun, an investigator will turn off the lights and exit the room until the playlist is finished. The session ends with video content. Each participant will be given an identical playlist for each session. At the end of the session, the participant will complete the "Biosound Technologies Posttest" questionnaire to assess the perceived effects of the session.
All collected data will be deidentified and stored in a HIPAA compliant electronic medical record system called Therapy Appointment. After a participant in the treatment group has completed their treatment sessions, they will complete the same assessments given at intake. After the assessments are completed, an investigator will ask 2 open-ended questions and then will record a summary of their answers.
While Biosound Therapy rarely causes side effects, some people may experience dizziness or discomfort. While adverse reactions are rarely reported, a decreased sense of anxiety can feel unfamiliar to people who are used to a state of physiological increased awareness. As stated above, the BTS is a wellness device that was designed to provide relief and side effects are rarely reported. All participants will be told that they can stop treatment at any time during the session by leaving the treatment room. An investigator will be in close proximity to the treatment room at all times to provide any needed assistance during participants' sessions. Snacks, water, guidance and emotional support will be available to participants should they experience any side effects. Additionally, HRV allows subjects an opportunity to see a balanced and healthy state and can help center a client who may be feeling dizzy after sound massage. The investigators will record any adverse side effects reported by the participants.
The process measures of recruitment and retention rates, open-ended interview responses, and participant characteristics will be summarized using descriptive statistics. Due to the small sample size, the Wilcoxon signed-rank test will be used to determine changes in the variables for the intervention and control group.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Treatment Group | Experimental | Device: Biosound Therapy SystemThe treatment group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. The principal investigator will schedule two Biosound Therapy sessions per week for four weeks for all treatment group participants. The treatment sessions will not occur on consecutive days. All participants in the treatment group will listen to identical playlists. At the beginning of the BTS session, the participant will complete a session of HeartMath biofeedback. Next, the participant will receive approximately 30-40 minutes of music containing binaural beats synchronized with sound massage.The session will finish with gratitude-based video content. |
| Control Group | No intervention | –The control group will be given the following assessments at baseline and four weeks post-randomization: the Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder 7-item scale (GAD-7), Cambridge Brain Sciences (CBS) tasks, and the COVID-19 Persistent Symptom Questionnaire. Control group participants were given a complimentary Biosound Therapy session and a ten dollar gift card upon completion of their final assessments. |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- experiencing at least three symptoms that began or were intensified due to COVID
- able to provide documentation of a COVID-19 test older than 30 days.
- 20-65 years old.
Key exclusion criteria (4 listed)
- abusing alcohol or drugs
- having a pacemaker or any other implanted devices
- pregnancy
- history of the following conditions: blood clots, schizophrenia, seizures, recent head injury, and any acute physical injury
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Biosound Therapy SystemAlso: vibroacoustic therapy, biofeedback, binaural beatsBiosound Therapy consists of biofeedback, vibroacoustic therapy synchronized with music that plays binaural beats, and video content. | Device | Treatment Group |
Primary outcome
The Patient Health Questionnaire (PHQ-9)
Time frame: 4 weeks
9-item questionnaire assessing for Major Depressive Disorder
Generalized Anxiety Disorder 7-item scale (GAD-7)
Time frame: 4 weeks
7-item questionnaire assessing for generalized anxiety disorder
Cambridge Brain Sciences (CBS) tasks
Time frame: 4 weeks
The CBS tasks measure reasoning, short-term memory, and verbal ability through 12 online tasks simulating puzzles or video games.
COVID-19 Persistent Symptom Questionnaire.
Time frame: 4 weeks
The authors developed The COVID-19 Persistent Symptom Questionnaire to measure common persistent COVID-19 symptoms at their worst over the last week on a scale of 0-3.
3 secondary outcomes
Recruitment Rate
Time frame: Through study completion, an average of 1 year
Retention Rate
Time frame: 4 weeks
Open-ended questions to participants about their experience
Time frame: 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 May 2023.
- Individual participant dataSharing planned: Yes. Any researchers who are interested in replicating the study or using the de-identified IPD can contact the principal investigator for a copy of the data set.
Related trials for Long COVID
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Recruiting
Whole-body Cryotherapy in Those With Chronic Fatigue: A Feasibility Study
ME/CFS, Fibromyalgia (FM)
Not yet recruitingPhase 3
The Study of Brave-LC LDN Treatment Trial
Post-acute COVID-19 Syndrome
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Enrolling by invitationPhase 2
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2
Systemic Inflammation, Neuroinflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Colleenia R Korapatti, MA principal investigator
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Biosound Therapy System in people with Long COVID, run by Anxiety Relief Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 May 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The Patient Health Questionnaire (PHQ-9) (time frame: 4 weeks). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 May 2023.